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trials’ data were retrieved from the Haute Autorité de Santé (HAS) website and the 
Number Needed to Treat (NNT) to prevent one event (progression, death) was esti-
mated. An Absolute Loss of Chance (ALOC) index was calculated over the time-lag 
period and per time unit combining NNT and HAS target population size. Drugs 
with level 5 Added Medical Value (ASMR, Amélioration du Service Médical Rendu) 
were excluded. Results: Twelve drugs were granted a EUMA for solid tumours in 
2012 and 2013 with level 2-4 Added Medical Value: one drug of level 2-important 
(trastuzumab emtansine), five drugs of level 3-moderate (cabazitaxel, vemurafenib, 
critzotinib, pertuzumab, and enzalutamide), and six drugs of level 4-minor (eribu-
line, ipilimumab, abiraterone, vandetanib, axitinib, and vismodegib). The time-lags 
between EUMA and FPRD ranged from 7.4 months (enzatulamide) to 29.9 months 
(cabazitaxel). Concurrently, the overall ALOC ranged from 9 to 799 medical events 
which might have not been prevented unless alternative access (Compassionate, 
Clinical Trials), depending on drug, indication and time-lag. ConClusions: Early 
patient access for innovative drugs in oncology might help preventing a substantial 
number of progressions and deaths. ALOC might support patient access decision 
making process.
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objeCtives: The aim of this study was to assess the burden of hospitalizations for 
metastatic renal cell carcinoma (mRCC) from 2008 to 2013 in France. Methods: A 
retrospective analysis was performed using the French national hospital database 
(PMSI). Hospital stays for mRCC between 2008 and 2013 were identified by combining 
the International Classification of Diseases-10threvision (ICD-10) codes for renal cell 
carcinoma (C64) and codes for metastasis (C77 or C78 or C79). Among hospital stays, 
incident cases were selected and followed for at least 1 year. Descriptive analyses 
were performed with a focus on hospital stays and patient characteristics. Results: 
Overall, 26 124 adult patients (median age at diagnosis 71 years [18-102] years); 
67.8 % male) were hospitalized for mRCC, corresponding to 123 385 hospital stays 
mainly in public settings (80.1%). Among those patients, 13 517 (51.7 %) had lung 
metastasis, 10 149 (38.8%) had bone and bone marrow metastasis, 7 553 (28.9%) 
had liver metastasis and 3 538 (13.5%) had brain metastasis. The number of new 
cases per year was stable while the number of hospitalizations increased 37.4% 
from 2008 to 2013. Death in a hospital setting was reported for 4 443 (17%) patients. 
During the study period, there were 36 205 (29.3%) hospital stays for chemotherapy 
and immunotherapy, 9 400 (7.6%) hospital stays for radiotherapy and 5 956 (4.8%) 
hospital stays for palliative care. The mean length of stay at diagnosis was 10.1 (SD: 
13.9) vs. 4.4 (SD: 9.3) days for subsequent stays. ConClusions: To our knowledge 
this is the first study to provide an overview of the burden of mRCC in French hos-
pitals between 2008 and 2013 and constitutes the preliminary step in assessing the 
economic burden of hospitalizations for mRCC.
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objeCtives: The aim of this study was to describe the burden of metastatic mela-
noma in public and private hospitals between 2008 and 2013 in France. Methods: 
The French national hospital database (PMSI) was analyzed to identify adults 
newly diagnosed with metastatic melanoma between 2008 and 2013. Using the 
International Classification of Diseases 10threvision codes for melanoma (C43) and 
for metastasis (C77 or C78 or C79), the number of hospital admissions for metastatic 
melanoma was identified and thereafter the corresponding number of hospitalized 
patients was determined. Descriptive analyses were performed with a focus on 
hospital stays and patient characteristics. Results: Between 2008 and 2013, 16 188 
patients (median age at diagnosis 66 years [18 -103]; 54.6 % male) were hospitalized 
for metastatic melanoma, corresponding to 104 731 hospital admissions mainly in 
public settings (94.8%). We identified 27 523 (26.3%) hospital admissions for chemo-
therapy and immunotherapy and only 2 943 (2.8%) hospital admissions for pallia-
tive care. 24.0% of diagnosis related groups were classified as surgery procedures. 
Hospital admissions were mainly performed in three regions: Ile-de-France (18.6%), 
Rhône Alpes (13.1%) and Aquitaine (12.6%). The mean length of stay was 3.2 days (SD: 
7.1). 39.8% of patients had 1 site of metastasis, 18.0% had 2 sites of metastasis and 
42.1% had at least 3 sites of metastasis. The most common sites of metastasis were 
lung in 36.8% of patients, liver in 28.8% of patients and brain in 27.8% of patients. 
Death in a hospital setting was reported for 10.3% of patients. ConClusions: This 
analysis allows us to strengthen our knowledge regarding the burden of metastatic 
melanoma which represents a first step in assessing the cost of hospitalizations 
related to metastatic melanoma. Such analysis is useful for economic modeling 
especially with the arrival of innovative treatments.
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objeCtives: There is an acute problem concerning lymphoma treatment in 
Ukraine. Previously, due to unavailability of up-to-date chemotherapy (CT) regimes, 
only 20% of lymphoma patients had a chance for persistent remission after the 
treatment, 40-60% of patients had response to treatment and only 35% of patients 
had 5-year survival rates. Todays clinical protocols of therapy in lymphoma patients 
take into account world’s experience. Methods: Clinical Practice Guidelines for the 
Diagnosis and Management of Lymphoma. A National Health and Medical Research 
illomavirus vaccine acceptance in Asian populations. Methods: Students studying 
undergraduate health professional courses (Medicine, Dentistry, Pharmacy, Nursing) 
in a private medical University in Kuala Lumpur, Malaysia in the period from June 
2014 - January 2015 were selected. The participants’ demographic details were gath-
ered by a self-administered questionnaire. The contingent valuation method was 
used to assess each respondent’s willingness to pay to take HPV vaccination and 
reduce the risk of cervical cancer. This method represents a single “take it or leave it 
offer”, whereby people are asked if they are willing to pay a specific pre-determined 
price for the benefit presented. Results: The mean age of the respondents was 23.5 
years, (SD ±1. 0). 55.2% reported as being in a relationship. Most of the participants 
were willing to pay an amount up to RM 500 to receive HPV vaccination. The median 
WTP for HPV vaccination is RM 465. Age, gender, and the patient’s perceived health 
status at baseline were not associated with WTP. Respondents who are in a relation-
ship (committed and dating) showed greater interest in vaccinating themselves and 
the relationship status emerged as unique predictors; Committed (OR= 2.20, P < 0.05) 
and dating (OR = 2.20, P< 0. 05). ConClusions: Avoidance of human papillomavirus 
infection and cervical cancer may have considerable value to the undergraduate 
students of health professional courses and this data will help future validation in 
a larger population in Malaysia.
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objeCtives: High cost and highly effective cancer treatment are changing the 
survivorship landscape with implications for pharma, payers and patients. High 
initial cost of care may be mitigated by lower global cost of care and significantly 
lower subsequent year cost. However, such long term value may be lost if patients 
switch coverage at general market frequency. We compared published benchmark 
coverage switch data to a breast cancer and non-cancer cohort to evaluate if patients 
with a cancer diagnosis are less likely to switch coverage. Methods: Breast cancer 
patients and a control group of non-cancer patients were identified using data 
obtained from the Cardinal Health Specialty Solutions Revenue Cycle Management 
(RCM) medical claims database. Patients had a claim during the 12 month period 
ending April 2014, were 60 years old or younger, diagnosed as of 2011 or later, and 
had at least 3 years of follow-up data available. Payer information at index period 
and at time of switch was recorded and insurance patterns examined. Data was ana-
lyzed using a chi-square test and Kaplan-Meier graphs. Results: There were 1440 
patients with breast cancer and 3950 patients with non-cancer diagnoses in the final 
study sample. Breast cancer patients switched payer at a statistically lower propor-
tion than the non-cancer control group, 22.7% versus 26.0% respectively (p= 0.014). 
Time to payer switch estimated through a Kaplan-Meier analysis demonstrated 
a longer time to payer switch for breast cancer patients versus the control group 
(3.59 years versus 3.56 years, p= 0.037). ConClusions: Despite protection against 
pre-existing condition uninsurability, a lower proportion of breast cancer patients 
switched payers during the study time window and had a longer estimated time 
to payer switch. Such trends will be of interest to payers and pharma as both seek 
understanding of value based care for their respective businesses.
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objeCtives: HCV infection caused 1,2 million DALY in 2002 in Europe and 200 104 
YLDs. 1% of these YLDs resulted from HCV-related hepatocellular carcinoma. The 
objective of the present study is to calculate the DALY for patients with HCV-related 
HCC in Bulgaria. Methods: It is a retrospective real-life observational study of 445 
patients with hepatocellular carcinoma registered in the National Cancer Registry 
for 2-year period (2012-2014). Data on demographic, clinical characteristics, previ-
ous, and concomitant diseases of the liver was collected from the patient registries. 
DALYs for these patients wàs calculated based on the WHO methodology. Results: 
350 of the observed patients were diagnosed with HCC in 3rd and 4th stage and 280 
of the patients were in productive ages. The mortality rate was significantly high – 
83% for the observed period. Chronic HCV infection and cirrhosis were found to be 
leading pathology for the development of HCC as ~ 20% of the patients with HCC 
and previous/concomitant liver diseases reported chronic hepatitis C infection and 
cirrhosis. For the 445 patients were calculated 798 years life lost (YLL) and 958 years 
lived with disability (YLD). DALY accounted for 1756. ConClusions: HCV-related 
cirrhosis and HCC implicit high social burden. The high mortality rate causes huge 
productivity losses for the society.
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objeCtives: Our objectives were to report time-lags between European Marketing 
Authorisation (EUMA) and French Pricing and Reimbursement Decision (FPRD) for 
recent innovative anti-cancer drugs and to quantify the corresponding patient loss 
of chance. Methods: We included 2012-2013 EMA-approved anti-cancer drugs in 
solid tumours and calculated the time-lag between EUMA and FPRD. Official pivotal 
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value-based pricing, which reflects disease burden, therapeutic innovation, and 
social values, is suggested. This study attempts to measure the importance of cost-
effectiveness and other values for a new anticancer drug. Methods: Through 
literature reviews and experts’ advices, eight health insurance benefit criteria 
were selected: disease severity, size of population affected by disease, pediatric 
medicine, alternative drugs, innovativeness, clinical benefit, cost-effectiveness, and 
budget impact. Preference for the criteria was investigated by using Discrete Choice 
Experiments(DCE), Analytic Hierarchy Process (AHP), swing weighting (SWING), and 
direct point allocation (DIRECT). The survey was conducted in three hundred general 
population through face to face interview. Respondents were selected using strati-
fied random sampling by age, sex and region. The conditional logistic regression for 
DCE was conducted with STATA ver.12. Results: In the preference investigation 
using DCE, people preferentially considered disease severity (OR: 1.837, 95% CI: 1.673 
to 2.017), alternative drugs (OR: 1.556, 95% CI: 1.458 to 1.661), and size of population 
affected by disease (OR: 1.408, 95% CI: 1.285 to 1.543). According to the results by 
using AHP, respondents considered clinical benefit to be the most important, fol-
lowed by cost-effectiveness and disease severity as the main evaluation items. As 
estimated by SWING and DIRECT, clinical benefit was also evaluated as the most 
important item. There was no difference in the first to third priority evaluation 
items between SWING and DIRECT. ConClusions: The priorities derived from all 
methodologies show that clinical benefit and disease severity were more important 
than cost-effectiveness in general terms. In the situation where decision-making is 
mostly centered on cost-effectiveness, our results may be seen as the social demand 
that clinical benefit and the influence of applicable disease should be reflected 
appropriately in the insurance coverage.
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objeCtives: The aim of our study is to analyse the biosimilar bids of the Hungarian 
National Health Insurance Fund Administration in case of colony-stimulating fac-
tor (CSF) products. Methods: Data derived from the nationwide pharmaceutical 
database of Hungarian National Health Insurance Fund Administration (NHIFA). We 
analysed how the number of patients treated by colony-stimulating factor products 
changed before (01.07.2011.-30.06.2012.) and after (01.07.2012.-30.06.2014.) the first 
biosimilar bid performed in March 2012 in Hungary. Results: In the 12 months 
before biosimilar bid 27,367 patients received colony-stimulating factor treatment, 
while in the first 12 months after the bid 26,149 patients, resulting in a 4.5 % decline. 
The second 12 months after the bid 28,463 patients received colony-stimulating 
factor treatment, resulting in a 4.0 % increase. Before the biosimilar bid, the NHIFA 
spent 7.49 billion Hungarian Forint (HUF) health insurance reimbursement for CSF 
products, which decreased by 44 % to 4.19 billion HUF in the first year after bio-
similar bid. ConClusions: The analyses of the Hungarian price competition bid 
of biosimilar products showed a minimal decline in the number of patients under 
treatment by colony-stimulating factor products while the health insurance reim-
bursement of these drugs significantly decreased.
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objeCtives: To assess the ability of G-CSF (Granulocyte-Colony Stimulating Factors) 
biosimilars (G-CSF-BIOSIM) to compete with their reference (REF) within the same 
therapeutic class by analyzing EU-5 and Japanese G-CSF markets and the factors 
influencing G-CSF-BIOSIM uptakes, 3 years after a same analysis carried out in 
2011. Methods: Data on medicine volumes, values and ex-manufacturer prices for 
all G-CSF categories in the EU-5 and in Japan were provided by IMS Health. Volumes 
were calculated in DDD (Defined Daily Doses) and prices in euros per DDD. Results: 
There are two G-CSF market profiles: i) countries with a high retail market distribu-
tion (R) which are the largest G-CSF markets with low global G-CSF-BIOSIM uptakes 
(11.8% in France and 12.8% in Germany); ii) countries with a dominant hospital chan-
nel (H) which are the smallest markets with higher G-CSF-BIOSIM uptakes (56.8% in 
Spain, 40.7% in the UK and 25.2% in Italy). Japan is a special case: H market and 12.0% 
G-CSF-BIOSIM uptakes (G-CSF-BIOSIM arrived latter in Japan than in Europe). The 
G-CSF-BIOSIM uptakes depend critically on their market access at a local/regional 
level. The more the decisions are decentralized (hospitals, local purchasing structures) 
the more their uptakes are high (51.4% of the hospital market in France and 40.7% 
in the UK). The price discount between G-CSF-BIOSIM and REF plays a marginal role 
globally (-7.8% in France, and +12.2% in the UK). ConClusions: Global G-CSF-BIOSIM 
uptakes sharply increased in EU-5 countries between 2011 and 2014 (e.g. +358% in 
Spain in volume, +119% in France). We confirm the results of our first study: there 
are two G-CSF market profiles and the competition with G-CSF-BIOSIM is not mainly 
based on prices, but on local political options. The study should now be extended to 
other countries to definitively validate these results.
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Council’ (Australia, December 2005) was chosen by the working group as one of 
key prototypes of the best medical practice in lymphoma patients on evidence-
based medicine. The working group has conducted an additional search for original 
sources of scientific information in order to justify the choice of CT. The results of 
search were presented as evidence tables according to the efficacy of various CT 
regimes. In general, 56 sources have been analyzed. Results: Clinical protocols in 
lymphoma patients with taking into account the obtained data have been devel-
oped. They included medical technologies with proven efficacy. However, it should 
be noted that some of the CT schemes with sufficient efficacy in clinical trials in 
patients with recurrent and refractory forms of lymphoma, high grade of aggressive 
non-Hodgkin lymphoma include bortezomib, vinorelbine, gemcitabine, carboplatin, 
cisplatin. These agents are not licensed for lymphoma, that results in impossibility 
to prescribe such regimes to patients. ConClusions: The up-to-date CT regimes 
allow achieving better results. However, the treatment is expensive, but prolongs 
survival and improves quality of life. Thus, introduction of modern approaches 
to the treatment of lymphomas in Ukraine and harmonization of Ukrainian and 
world’s practices will provide comprehensive and effective medical care for patients.
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objeCtives: Breast cancer is the most common cancer in women in England and 
the second most common cause of cancer death. In 2011, there were > 40,000 new 
breast cancer cases and > 10,000 deaths, with delay to diagnosis thought to be an 
attributing factor. Our aim was to map out the breast cancer diagnostic pathways for 
women in England, quantify the number of women proceeding through each step 
of the pathway, and compare it to the pathway in France and Germany. Methods: 
We performed literature searches for peer-reviewed papers and other published 
data from England, and conducted semi-structured interviews with cancer experts 
to understand the breast cancer diagnostic process. A patient pathway framework 
for diagnosis was modelled in Microsoft Excel and patient flow was quantified 
with published data and our own calculations where there were missing data. We 
validated the model with data from France and Germany. Results: England’s 
well-organised National Health Service Breast Screening Programme (NHSBSP) 
identifies women with early stage breast cancer to manage them promptly. Whilst 
NHSBSP coverage is 75% of invited women, only 40% of all malignancies are identi-
fied through screening, with the remaining cases from symptomatic referrals to 
breast services. We estimated that ~230,000 women present in general practice with 
breast symptoms annually and are referred to breast services, an estimated 46,000 
symptomatic women have biopsies, yielding 24,528 malignant cases. The ratio of 
women attending breast services, having a biopsy, and having a malignancy differ 
between screened and symptomatic women. The diagnostic pathway is similar in 
France and Germany, although the proportion identified through screening dif-
fers. ConClusions: Data on the full breast cancer diagnostic pathway are sparse, 
especially for women with symptoms. Our complete diagnostic pathway gives a full 
understanding about the diagnostic process, tests conducted, and quantifies the 
burden on healthcare services.
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objeCtives: Radiation oncologists and radiation therapists are key medical 
personnel involved with radiation therapy (RT). The objective was to determine 
costs associated with RT-personnel using provincial (Ontario) administrative data-
bases. Methods: A cohort of women diagnosed with primary breast cancer (BC) 
(ICD-9 174.x) was identified from the Ontario Cancer Registry (2007-2010) with up 
to one year follow-up timeframe. Radiation oncologists bill patient visits to the 
Ontario Health Insurance Plan (OHIP). Visits with $0 charge were excluded. Radiation 
therapists record planning and treatment workloads (conventional and intensity 
modulated RT or IMRT) using National Health Productivity Improvement Program 
(NHPIP) activity codes in the Activity Level Reporting (ALR) database. An hourly 
wage was then applied to these codes to determine costs within the first year 
after diagnosis. Results: We identified 30,338 women diagnosed with primary BC, 
86% (N= 26,121) of whom visited a radiation oncologist. The average cost of these 
visits per patient was $1,013 ± $607. The total number of visits was 165,060 and the 
total cost was $26.5 million. Approximately 62% of the cohort received planning 
(N= 18,859) and treatment (N= 18,758) for conventional RT by radiation therapists and 
the average cost per patient was $479 ± $326 and $282 ± $176, respectively. The total 
planning and treatment cost for conventional RT was $9.0 million and $5.3 million, 
respectively. For IMRT planning (N= 1,631) and treatment (N= 5,883), the average cost 
per patient was $158 ± $84 and $637 ± $297, respectively. The total planning and 
treatment cost for IMRT was $258,239 and $3.7 million, respectively. The overall cost 
of radiation oncologist and RT visits was $44.8 million. ConClusions: Personnel 
costs for delivering RT to breast cancer patients in the first year after their diagno-
sis are significant. Future work will be to incorporate the cost of other personnel 
involved with RT, such as medical physicists and nurses.
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objeCtives: The cost-effectiveness, based on economic evaluation, has been 
an important basis for reimbursement decisison making in Korea. Recently, the 
